Literature DB >> 17278044

31P-MRS of skeletal muscle is not a sensitive diagnostic test for mitochondrial myopathy.

Tina Dysgaard Jeppesen1, Bjørn Quistorff, Flemming Wibrand, John Vissing.   

Abstract

Clinical phenotypes of persons with mitochondrial DNA (mtDNA) mutations vary considerably. Therefore, diagnosing mitochondrial myopathy (MM) patients can be challenging and warrants diagnostic guidelines. (31)phosphorous magnetic resonance spectroscopy ((31)P-MRS) have been included as a minor diagnostic criterion for MM but the diagnostic strength of this test has not been compared with that of other commonly used diagnostic procedures for MM. To investigate this, we studied seven patients with single, large-scale deletions-, nine with point mutations of mtDNA and 14 healthy subjects, who were investigated for the following: 1) (31)P-MRS of lower arm and leg muscles before and after exercise, 2) resting and peak-exercise induced increases of plasma lactate, 3) muscle morphology and -mitochondrial enzyme activity, 4) maximal oxygen uptake (VO(2max)), 5) venous oxygen desaturation during handgrip exercise and 6) a neurological examination. All MM patients had clinical symptoms of MM, > 2% ragged red fibers in muscle, and impaired oxygen desaturation during handgrip. Fourteen of 16 patients had impaired VO(2max), 10/16 had elevated resting plasma lactate, and 10/11 that were investigated had impaired citrate synthase-corrected complex I activity. Resting PCr/P(i) ratio and leg P(i) recovery were lower in MM patients vs. healthy subjects. PCr and ATP production after exercise were similar in patients and healthy subjects. Although the specificity for MM of some (31)P-MRS variables was as high as 100%, the sensitivity was low (0-63%) and the diagnostic strength of (31)P-MRS was inferior to the other diagnostic tests for MM. Thus, (31)P-MRS should not be a routine test for MM, but may be an important research tool.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17278044     DOI: 10.1007/s00415-006-0229-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  39 in total

1.  31P MRS measurement of mitochondrial function in skeletal muscle: reliability, force-level sensitivity and relation to whole body maximal oxygen uptake.

Authors:  D E Larson-Meyer; B R Newcomer; G R Hunter; H P Hetherington; R L Weinsier
Journal:  NMR Biomed       Date:  2000-01       Impact factor: 4.044

2.  Cycle ergometry is not a sensitive diagnostic test for mitochondrial myopathy.

Authors:  Tina Dysgaard Jeppesen; David Olsen; John Vissing
Journal:  J Neurol       Date:  2003-03       Impact factor: 4.849

3.  Direct measurement of high-energy phosphate compounds in patients with neuromuscular disease.

Authors:  M A Tarnopolsky; G Parise
Journal:  Muscle Nerve       Date:  1999-09       Impact factor: 3.217

4.  ADP recovery after a brief ischemic exercise in normal and diseased human muscle--a 31P MRS study.

Authors:  Z Argov; N De Stefano; D L Arnold
Journal:  NMR Biomed       Date:  1996-06       Impact factor: 4.044

5.  Familial mitochondrial encephalomyopathy (MERRF): genetic, pathophysiological, and biochemical characterization of a mitochondrial DNA disease.

Authors:  D C Wallace; X X Zheng; M T Lott; J M Shoffner; J A Hodge; R I Kelley; C M Epstein; L C Hopkins
Journal:  Cell       Date:  1988-11-18       Impact factor: 41.582

6.  Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients.

Authors:  Montse Laguno; Ana Milinkovic; Elisa de Lazzari; Javier Murillas; Esteban Martínez; Jose Luis Blanco; Montse Loncá; Alejandra Biglia; Agathe Leon; Mercedes García; Maria Larrousse; Felipe García; Jose Maria Miró; Jose Maria Gatell; Josep Mallolas
Journal:  Antivir Ther       Date:  2005

7.  Lactate turnover at rest and during submaximal exercise in patients with heart failure.

Authors:  S D Katz; B Bleiberg; J Wexler; K Bhargava; J J Steinberg; T H LeJemtel
Journal:  J Appl Physiol (1985)       Date:  1993-11

8.  Bioenergetic heterogeneity of human mitochondrial myopathies: phosphorus magnetic resonance spectroscopy study.

Authors:  Z Argov; W J Bank; J Maris; P Peterson; B Chance
Journal:  Neurology       Date:  1987-02       Impact factor: 9.910

9.  In vivo muscle magnetic resonance spectroscopy in the clinical investigation of mitochondrial disease.

Authors:  P M Matthews; C Allaire; E A Shoubridge; G Karpati; S Carpenter; D L Arnold
Journal:  Neurology       Date:  1991-01       Impact factor: 9.910

10.  Investigation of human mitochondrial myopathies by phosphorus magnetic resonance spectroscopy.

Authors:  D L Arnold; D J Taylor; G K Radda
Journal:  Ann Neurol       Date:  1985-08       Impact factor: 10.422

View more
  10 in total

1.  Bedside-to-Bench conference: research agenda for idiopathic fatigue and aging.

Authors:  Neil B Alexander; George E Taffet; Frances McFarland Horne; Basil A Eldadah; Luigi Ferrucci; Susan Nayfield; Stephanie Studenski
Journal:  J Am Geriatr Soc       Date:  2010-05       Impact factor: 5.562

2.  Skeletal muscle reoxygenation after high-intensity exercise in mitochondrial myopathy.

Authors:  Daniela M Bravo; Ana Cristina Gimenes; Rúbia B Nascimento; Eloara V M Ferreira; Ana Cristina B Siqueira; Ethiane D S Meda; J Alberto Neder; Luiz Eduardo Nery
Journal:  Eur J Appl Physiol       Date:  2011-09-04       Impact factor: 3.078

Review 3.  MR compatible ergometers for dynamic 31P MRS.

Authors:  Petr Sedivy; Monika Dezortova; Jan Rydlo; Miloslav Drobny; Martin Krssak; Ladislav Valkovic; Milan Hajek
Journal:  J Appl Biomed       Date:  2019-04-15       Impact factor: 1.797

4.  A plasma signature of human mitochondrial disease revealed through metabolic profiling of spent media from cultured muscle cells.

Authors:  Oded Shaham; Nancy G Slate; Olga Goldberger; Qiuwei Xu; Arvind Ramanathan; Amanda L Souza; Clary B Clish; Katherine B Sims; Vamsi K Mootha
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-08       Impact factor: 11.205

5.  Submaximal exercise testing with near-infrared spectroscopy in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patients compared to healthy controls: a case-control study.

Authors:  Ruth R Miller; W Darlene Reid; Andre Mattman; Cristiane Yamabayashi; Theodore Steiner; Shoshana Parker; Jennifer Gardy; Patrick Tang; David M Patrick
Journal:  J Transl Med       Date:  2015-05-20       Impact factor: 5.531

6.  Investigating Muscle Function After Stroke Rehabilitation with 31P-MRS: A Preliminary Study.

Authors:  Shuai Zhang; Min Chen; Lei Gao; Ying Liu
Journal:  Med Sci Monit       Date:  2018-05-06

Review 7.  Fatigue and exercise intolerance in mitochondrial diseases. Literature revision and experience of the Italian Network of mitochondrial diseases.

Authors:  M Mancuso; C Angelini; E Bertini; V Carelli; G P Comi; C Minetti; M Moggio; T Mongini; S Servidei; P Tonin; A Toscano; G Uziel; M Zeviani; G Siciliano
Journal:  Neuromuscul Disord       Date:  2012-12       Impact factor: 4.296

8.  31P MR spectroscopy and computational modeling identify a direct relation between Pi content of an alkaline compartment in resting muscle and phosphocreatine resynthesis kinetics in active muscle in humans.

Authors:  Joep W M van Oorschot; Joep P J Schmitz; Andrew Webb; Klaas Nicolay; Jeroen A L Jeneson; Hermien E Kan
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

Review 9.  Mitochondrial diseases.

Authors:  Young-Mock Lee
Journal:  J Epilepsy Res       Date:  2012-03-30

Review 10.  Monitoring clinical progression with mitochondrial disease biomarkers.

Authors:  Hannah E Steele; Rita Horvath; Jon J Lyon; Patrick F Chinnery
Journal:  Brain       Date:  2017-10-01       Impact factor: 13.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.